Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZEPOXIDE HYDROCHLORIDE versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZEPOXIDE HYDROCHLORIDE versus PAXIPAM.
CHLORDIAZEPOXIDE HYDROCHLORIDE vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptor, enhancing GABA-mediated chloride ion influx, leading to neuronal hyperpolarization and reduced excitability.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
Oral: 5-25 mg 3-4 times daily, up to 100 mg/day in severe anxiety; IM/IV: 50-100 mg initially, then 25-50 mg 3-4 times daily.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6.6 to 28 hours (parent drug); clinically, duration of effect may be prolonged due to active metabolite nordazepam (half-life 30-100 hours), especially in elderly or hepatic impairment.
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Renal: approximately 50-60% as metabolites (mainly conjugated forms), with less than 1% unchanged. Fecal: minor, about 10%. Biliary excretion contributes to enterohepatic circulation.
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine